Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited
Your view on BXPHF
Overview
What the company does, where it operates, and who runs it.
About Botanix Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howie McKibbon
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Howie McKibbon
- Headquarters
- D2, 661 Newcastle Street, Leederville, WA, AU
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections.
Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.
The company was incorporated in 1984 and is based in Leederville, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Botanix Pharmaceuticals Limited, and the rating behind it. BXPHF last traded at $0.05; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Botanix Pharmaceuticals Limited. Starting points for Botanix Pharmaceuticals Limited: EPS -$0.03, beta 1.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Botanix Pharmaceuticals Limited. Trailing twelve-month EPS for Botanix Pharmaceuticals Limited stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Botanix Pharmaceuticals Limited valued side by side against its closest peers. Botanix Pharmaceuticals Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Botanix Pharmaceuticals Limited, and how their positions are changing. At a $89.0M market value, institutional positions materially move Botanix Pharmaceuticals Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Botanix Pharmaceuticals Limited executives and directors. Shares of Botanix Pharmaceuticals Limited have traded between $0.03 and $0.34 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Botanix Pharmaceuticals Limited. Botanix Pharmaceuticals Limited is a $89.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Botanix Pharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Botanix Pharmaceuticals Limited. Coverage tracks Botanix Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.